[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100514651":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":27,"responsibleParty":45,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":10,"maxAge":10,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":10,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Tri-Service General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Systematic joint and bone health assessments before and after enrollment",null,"1. Haemophilia Early Arthropathy Detection :HEAD-US, HJHS, and DEXA scan\n2. serum markers : CTX-II, COMP, hsCRP, TNF-a, CTX-I, sRANKL, OPG, and Osteopontin (OPN)\n3. Quality of life assessments (Haem-A-QoL, EQ-5D)",[13],"Diagnostic Test: serum biomarker.",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","serum biomarker.","serum biomarker:CTX-II, COMP, hsCRP, TNF-a, CTX-I, sRANKL, OPG, and Osteopontin (OPN)",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},"Yeu-Chin Chen","CONTACT","(+886)2-87923311","13654","yeuchin99@gmail.com",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Tri-Service General Hospital Hemophilia Care Center","RECRUITING","Taipei","Neihu Dist.","114202","Taiwan","TW",{"type":37,"coordinates":38},"Point",[39,40],121.52639,25.05306,{"lat":40,"lon":39},[43],{"name":44,"role":23,"phone":24,"phoneExt":25,"email":26},"Yeu-Chin chen",{"type":46,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Chen Yeu-Chin","Director of the Hemophilia Center","100514651","a-study-on-the-bone-health-effectiveness-of-applying-recombinant-factor-viii-fc-rfviiifc-to-patients-with-hemophilia-a-prototype-a-100514651",false,"NCT05981274","A Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A)","A Prospective and Retrospective Interventional Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A)","Inclusion Criteria:\n\n1. Patients with severe hemophilia A (all ages).\n2. Patients with moderate type hemophilia A with hemophilic arthropathy.\n3. Currently on rFVIIIFc regular prophylaxis and have previous medical record with regular prophylaxis with standard half-life product for one year\n4. Able and willing to undergo joint and bone examinations\n\nExclusion Criteria:\n\n1. Participants of other interventional studies.\n2. Patients with current inhibitors.\n3. History of major neurological disease (eg. Stroke, Parkinson's disease, neuropathy, etc.)\n4. History of major psychiatric disease (eg. Schizophrenia, bipolar disorder)\n5. Significantly impaired vision\u002Fhearing",true,"MALE",{"count":59,"type":60},45,"ESTIMATED","OBSERVATIONAL","Study Objectives\\*\n\n1. Provide a systematic evaluation of the treatment outcomes in patients with hemophilia A\n2. Emphasize the importance and clinical benefits of rFVIII-Fc in joint and bone health.\n3. Compare the clinical outcomes from 1 year before and after switching to EHL.\n4. Exploratory: Identify biomarkers that could provide more useful and convenient evaluations of joint and bone health. (Time-saving and easy to monitor)",[64],"Severe Hemophilia A Without Inhibitor","2024-04-08",{"date":67,"type":68},"2024-04-10","ACTUAL",{"date":70,"type":68},"2023-07-14",{"date":72,"type":60},"2027-12-31",{"name":5,"class":6},1]